Laekna, Inc. is engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease, and is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor, the LAE001 is an androgen synthesis inhibitor. The company was established in 2016 and is headquartered in Hong Kong, China.
Headquarters
5Th Floor, No. 987 Cailun Road, Zhangjiang Hi-Tech Park, Pudong New District
Shanghai; Shanghai;
Contact Details: Purchase the Laekna, Inc. report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service